Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK4 | Q16654 | 1/20 | 0.51 |
| ▸ | GRM1 | Q13255 | 11/20 | 0.50 |
| ▸ | GRM5 | P41594 | 10/20 | 0.50 |
| ▸ | HTR6 | P50406 | 1/20 | 0.47 |
| ▸ | CNR1 | P21554 | 2/20 | 0.45 |
| ▸ | EED | O75530 | 2/20 | 0.45 |
| ▸ | RBBP4 | Q09028 | 2/20 | 0.45 |
| ▸ | SUZ12 | Q15022 | 2/20 | 0.45 |
| ▸ | EZH2 | Q15910 | 2/20 | 0.45 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.45 |
| ▸ | CDK9 | P50750 | 1/20 | 0.45 |
| ▸ | JAK1 | P23458 | 1/20 | 0.44 |
| ▸ | NAMPT | P43490 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26650792 | 0.85 | PDK4 (0.48) | PDK4GRM1GRM5HTR6CNR1 | |
| SCHEMBL30088583 | 0.85 | PDK4 (0.48) | PDK4GRM1GRM5HTR6CNR1 | |
| SCHEMBL19297151 | 0.84 | PDK4 (0.61) | PDK4GRM1GRM5HTR6CNR1 | |
| SCHEMBL19297056 | 0.79 | DGAT2 (0.59) | PDK4GRM1GRM5HTR6CNR1 | |
| SCHEMBL31342210 | 0.78 | CNR1 (0.55) | PDK4GRM1GRM5HTR6CNR1 | |
| SCHEMBL15556190 | 0.78 | CNR1 (0.55) | PDK4GRM1GRM5HTR6CNR1 | |
| SCHEMBL14611474 | 0.78 | PDK4 (0.56) | PDK4GRM1GRM5HTR6CNR1 | |
| SCHEMBL13993112 | 0.78 | GRM1 (0.57) | PDK4GRM1GRM5HTR6CNR1 | |
| SCHEMBL2476516 | 0.78 | PDK4 (0.56) | PDK4GRM1GRM5HTR6CNR1 | |
| SCHEMBL13993111 | 0.78 | GRM1 (0.57) | PDK4GRM1GRM5HTR6CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8877778-B2 | Benzofurane compounds | HOFFMANN-LA ROCHE INC. (US) | 2014-11-04 | — | — | US | disclosed |
| EP-2651929-A1 | NOVEL BENZOFURANE COMPOUNDS | F.HOFFMANN-LA ROCHE AG (CH) | 2013-10-23 | — | — | EP | disclosed |
| US-20120157449-A1 | BENZOFURANE COMPOUNDS | HOFFMANN-LA ROCHE INC. | 2012-06-21 | — | — | US | disclosed |
| WO-2012080149-A1 | NOVEL BENZOFURANE COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120157449-A1 | BENZOFURANE COMPOUNDS | HTR3A, HTR3C, HTR2A | PDK4 1272/4885GRM1 559/4885GRM5 470/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.